A citation-based method for searching scientific literature

You-Cai Zhu, Xin-Gen Zhang, Xue-Ping Lin, Wen-Xian Wang, Xiao-Feng Li, Li-Xin Wu, Hua-Fei Chen, Chun-Wei Xu, Kai-Qi Du. Oncol Lett 2019
Times Cited: 6







List of co-cited articles
17 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Klarisa Rikova, Ailan Guo, Qingfu Zeng, Anthony Possemato, Jian Yu, Herbert Haack, Julie Nardone, Kimberly Lee, Cynthia Reeves, Yu Li,[...]. Cell 2007
50

ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
50

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
50

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
33

Lung cancer.
Roy S Herbst, John V Heymach, Scott M Lippman. N Engl J Med 2008
33

ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes.
Amit Joshi, Nikhil Pande, Vanita Noronha, Vijay Patil, Rajiv Kumar, Anuradha Chougule, Vaishakhi Trivedi, Amit Janu, Abhishek Mahajan, Kumar Prabhash. Ecancermedicalscience 2019
9
33

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Sebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, Jeremy Franklin, Martin Sebastian, Enriqueta Felip, Christian Grohé, Delvys Rodriguez-Abreu, Diana S Y Abdulla, Helge Bischoff,[...]. J Thorac Oncol 2019
40
33

Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Ziming Li, Lan Shen, Ding Ding, Jia Huang, Jie Zhang, Zhiwei Chen, Shun Lu. J Thorac Oncol 2018
44
33

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
Kurtis D Davies, Anh T Le, Mariana F Theodoro, Margaret C Skokan, Dara L Aisner, Eamon M Berge, Luigi M Terracciano, Federico Cappuzzo, Matteo Incarbone, Massimo Roncalli,[...]. Clin Cancer Res 2012
292
33

Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Haiyan Xu, Quan Zhang, Li Liang, Junling Li, Zhefeng Liu, Weihua Li, Lu Yang, Guangjian Yang, Fei Xu, Jianming Ying,[...]. Cancer Med 2020
7
33

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
Julien Mazières, Gérard Zalcman, Lucio Crinò, Pamela Biondani, Fabrice Barlesi, Thomas Filleron, Anne-Marie C Dingemans, Hervé Léna, Isabelle Monnet, Sacha I Rothschild,[...]. J Clin Oncol 2015
238
33

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
33

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, Shun Lu, Jianying Zhou, Takashi Seto, Jin-Ji Yang, Noboru Yamamoto, Myung-Ju Ahn, Toshiaki Takahashi,[...]. J Clin Oncol 2018
137
33

Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer.
Liang Zeng, Yizhi Li, Lili Xiao, Yi Xiong, Li Liu, Wenjuan Jiang, Jianfu Heng, Jingjing Qu, Nong Yang, Yongchang Zhang. Onco Targets Ther 2018
10
33

Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations.
Yen-Fu Chen, Min-Shu Hsieh, Shang-Gin Wu, Yih-Leong Chang, Jin-Yuan Shih, Yi-Nan Liu, Meng-Feng Tsai, Tzu-Hsiu Tsai, Chong-Jen Yu, James Chih-Hsin Yang,[...]. J Thorac Oncol 2014
55
33

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J Solomon, Fiona Blackhall,[...]. N Engl J Med 2013
33

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
33

Early mortality of stage IV non-small cell lung cancer in the United States.
Arya Amini, Vivek Verma, Scott M Glaser, Ashwin Shinde, Sagus Sampath, William A Stokes, Chad G Rusthoven, Erminia Massarelli, Ravi Salgia, Laurie E Gaspar,[...]. Acta Oncol 2019
3
33

AKIP1 promotes angiogenesis and tumor growth by upregulating CXC-chemokines in cervical cancer cells.
Wenying Zhang, Qiongwei Wu, Chao Wang, Longtao Yang, Ping Liu, Chengbin Ma. Mol Cell Biochem 2018
34
16

AKIP1 promoted epithelial-mesenchymal transition of non-small-cell lung cancer via transactivating ZEB1.
Xiaobin Guo, Limin Zhao, Dongjun Cheng, Qing Mu, Hongyan Kuang, Keqing Feng. Am J Cancer Res 2017
26
16

AKIP1 promotes early recurrence of hepatocellular carcinoma through activating the Wnt/β-catenin/CBP signaling pathway.
Yanmei Cui, Xianqiu Wu, Chuyong Lin, Xin Zhang, Liping Ye, Liangliang Ren, Min Chen, Meisongzhu Yang, Yue Li, Mengfeng Li,[...]. Oncogene 2019
26
16


Overexpression of AKIP1 predicts poor prognosis of patients with breast carcinoma and promotes cancer metastasis through Akt/GSK-3β/Snail pathway.
Dan Mo, Xinning Li, Chunhong Li, Junrong Liang, Tian Zeng, Naiwei Su, Qipei Jiang, Jingjing Huang. Am J Transl Res 2016
27
16

A-kinase-interacting protein 1 (AKIP1) acts as a molecular determinant of PKA in NF-kappaB signaling.
Nan Gao, Yurina Hibi, Marni Cueno, Kaori Asamitsu, Takashi Okamoto. J Biol Chem 2010
61
16

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.
D Ross Camidge, Robert C Doebele, Keith M Kerr. Nat Rev Clin Oncol 2019
185
16

Characterization of a novel human breast cancer associated gene (BCA3) encoding an alternatively spliced proline-rich protein.
Richard Kitching, Haoxia Li, Michael J Wong, Shankary Kanaganayakam, Harriette Kahn, Arun Seth. Biochim Biophys Acta 2003
39
16

Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey.
Daniel Morgensztern, Shean Huey Ng, Feng Gao, Ramaswamy Govindan. J Thorac Oncol 2010
333
16

AKIP1 enhances NF-kappaB-dependent gene expression by promoting the nuclear retention and phosphorylation of p65.
Nan Gao, Kaori Asamitsu, Yurina Hibi, Takaharu Ueno, Takashi Okamoto. J Biol Chem 2008
60
16

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Tony S Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Min Lee, Rolf Linke, Rafael Rosell, Jesus Corral,[...]. J Clin Oncol 2018
239
16

High expression of CD8 predicts favorable prognosis in patients with lung adenocarcinoma: A cohort study.
Sheng-Lan Ye, Xue-Ying Li, Ke Zhao, Tao Feng. Medicine (Baltimore) 2017
24
16

A National Analysis of Short-term Outcomes and Long-term Survival Following Thoracoscopic Versus Open Lobectomy for Clinical Stage II Non-Small-Cell Lung Cancer.
Chi-Fu Jeffrey Yang, Arvind Kumar, John Z Deng, Vignesh Raman, Natalie S Lui, Thomas A D'Amico, Mark F Berry. Ann Surg 2021
22
16

A-kinase-interacting protein localizes protein kinase A in the nucleus.
Mira Sastri, David M Barraclough, Peter T Carmichael, Susan S Taylor. Proc Natl Acad Sci U S A 2005
105
16

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Haruhiro Saito, Tatsuro Fukuhara, Naoki Furuya, Kana Watanabe, Shunichi Sugawara, Shunichiro Iwasawa, Yoshio Tsunezuka, Ou Yamaguchi, Morihito Okada, Kozo Yoshimori,[...]. Lancet Oncol 2019
251
16


Non-small cell lung cancer, version 2.2013.
David S Ettinger, Wallace Akerley, Hossein Borghaei, Andrew C Chang, Richard T Cheney, Lucian R Chirieac, Thomas A D'Amico, Todd L Demmy, Ramaswamy Govindan, Frederic W Grannis,[...]. J Natl Compr Canc Netw 2013
297
16




PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations.
Andreas H Scheel, Sascha Ansén, Anne M Schultheis, Matthias Scheffler, Rieke N Fischer, Sebastian Michels, Martin Hellmich, Julie George, Thomas Zander, Michael Brockmann,[...]. Oncoimmunology 2016
73
16

Cancer treatment and survivorship statistics, 2016.
Kimberly D Miller, Rebecca L Siegel, Chun Chieh Lin, Angela B Mariotto, Joan L Kramer, Julia H Rowland, Kevin D Stein, Rick Alteri, Ahmedin Jemal. CA Cancer J Clin 2016
16

Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Terry L Ng, Yiwei Liu, Anastasios Dimou, Tejas Patil, Dara L Aisner, Zhengwei Dong, Tao Jiang, Chunxia Su, Chunyan Wu, Shengxiang Ren,[...]. Cancer 2019
42
16

Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
J Remon, L E Hendriks, C Cabrera, N Reguart, B Besse. Cancer Treat Rev 2018
27
16

EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.
Jean-Charles Soria, Tony S Mok, Federico Cappuzzo, Pasi A Jänne. Cancer Treat Rev 2012
104
16


A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.
Keith M Kerr, Erik Thunnissen, Urania Dafni, Stephen P Finn, Lukas Bubendorf, Alex Soltermann, Eric Verbeken, Wojciech Biernat, Arne Warth, Antonio Marchetti,[...]. Lung Cancer 2019
20
16

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Nathan T Ihle, Lauren A Byers, Edward S Kim, Pierre Saintigny, J Jack Lee, George R Blumenschein, Anne Tsao, Suyu Liu, Jill E Larsen, Jing Wang,[...]. J Natl Cancer Inst 2012
318
16

Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer.
Yosuke Miura, Noriaki Sunaga. Cancers (Basel) 2018
23
16

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
Chee Khoon Lee, Johnathan Man, Sally Lord, Wendy Cooper, Matthew Links, Val Gebski, Roy S Herbst, Richard J Gralla, Tony Mok, James Chih-Hsin Yang. JAMA Oncol 2018
266
16




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.